Sharekhan's research report on Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited reported steady numbers for Q1FY22, though PAT missed estimates due to a higher tax rate. The company derives ~60% of its sales collectively from the Indian and Brazil markets and the management sees these two geographies as key growth drivers. The Dahej and Indrad plants are under the USFDA’s scrutiny and post clearance, the company looks to launch 12-15 new products annually from the plants.
Outlook
Given the strong growth outlook across Indian and Brazilian business, we retain a Buy recommendation on the stock with an unchanged PT of Rs 3,400.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
